Talking about those legal threats

The South Florida Business Journal reported on the boom in compounded GLP-1s and Scott explained why the threat of (baseless) lawsuits from pharma companies can keep some pharmacists from talking about it.

Bonus: Both Eli Lilly and Novo Nordisk admitted to threatening compounders even without legal basis.

UK-based pharmaphorum is covering the GLP-1 issue on this side of the pond — specifically Lilly’s...

Our comment to FDA about its use of the Pharmacy Compounding Advisory Committee (PCAC) was covered...

Pharmaceutical Technology lets us tell ’em how we really feel about Novo asking the FDA to put...

Talking about those legal threats

Related posts

The Brits could have done better

Inside Health Policy covers our comment

Not holding back